



| | | | |
|-------------------|---|-----|-----------|
| Suggested Formula | Diltiazem Hydrochloride 240 mg Slow Release Oral Capsules (Powder Blend, 100 x Size #0 Capsules) | FIN | F 008 143 |
|-------------------|---|-----|-----------|

IMPORTANT: This formula is for a **slow release** capsule. Please note that the rate of drug release may not be identical to the release rates of commercial formulations labeled as sustained-release, sustained action, prolonged-action, controlled-release, extended-release, timed-release, targeted release, long-acting, modified-release, etc. As such, this preparation should be prescribed and monitored under the close supervision of the prescribing physician.

SUGGESTED FORMULATION

| Ingredient Listing | Qty. | Unit | NDC # | Supplier | Lot Number | Expiry Date |
|---|-------------|------|-------|----------|------------|-------------|
| Diltiazem Hydrochloride, USP | 24.000 | g | | | | |
| Hypromellose (4000 CPS) Methocel E4M, USP | TBD | | | | | |
| Cellulose (microcrystalline), NF | TBD | | | | | |
| Sodium Chloride, USP | As required | | | | | |





| | | | |
|-------------------|---|-----|-----------|
| Suggested Formula | Diltiazem Hydrochloride 240 mg Slow Release Oral Capsules (Powder Blend, 100 x Size #0 Capsules) | FIN | F 008 143 |
|-------------------|---|-----|-----------|

SPECIAL PREPARATORY CONSIDERATIONS

Ingredient-Specific Information

Light Sensitive (protect from light whenever possible):

Diltiazem Hydrochloride

Hygroscopic (protect from moisture whenever possible):

*Hypromellose (4000 CPS) Methocel E4M,
Cellulose (microcrystalline)*

Suggested Preparatory Guidelines

Non-Sterile Preparation Sterile Preparation

Processing Error /

Testing Considerations:

To account for processing error considerations during preparation, it is suggested to measure an additional **3 to 5%** of the required quantities of ingredients.

Special Instruction:

This formula may contain one or more Active Pharmaceutical Ingredients (APIs) that may be classified as hazardous, please refer & verify the current NIOSH list of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016. **General Chapter <800> Hazardous Drugs – Handling in Healthcare Settings** was formally published February 1, 2016 in the First Supplement to USP 39-NF 34 and has a delayed **official implementation date of December 31st, 2019**.

This formula must be prepared within the appropriate facilities under adequate environmental conditions, following the necessary guidelines and procedures as stated within *USP 795* and *USP 800*, when handling hazardous drugs. Only trained and qualified personnel must prepare this formula.

All required personal protective equipment (hazardous if applicable), such as but not limited to, lab coat, protective sleeves, gloves both inner and outer if applicable, dedicated shoe covers, hairnet, beard cover, eyewear, appropriate face mask, respirator and face shield, etc., where applicable must be worn at all times.

If applicable, follow all required procedures for hazardous drug handling including but not limited to procurement, transport, storage, preparation, dispensing, administration, clean up (spills) & disposal.

If you are a registered 503B facility, please refer to all relevant guidance documents including but not limited to the Code of Federal Regulations (CFR), Guidance for Industry (GFI) and Compliance Policy Guides (CPGs).

This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.



| | | | |
|-------------------|---|-----|-----------|
| Suggested Formula | Diltiazem Hydrochloride 240 mg Slow Release Oral Capsules (Powder Blend, 100 x Size #0 Capsules) | FIN | F 008 143 |
|-------------------|---|-----|-----------|

SUGGESTED PREPARATION (for 100 Size #0 Capsules)

Weigh and / or measure the following ingredients when appropriate:

| Ingredient Listing | Qty. | Unit | Multiplication factor (*): ____ | Processing Error | Qty. to measure |
|--|-------------|------|---------------------------------|------------------|-----------------|
| Diltiazem Hydrochloride, USP § | 24.000 | g | | | |
| Hypromellose (4000 CPS) Methocel E4M, USP § | TBD | | | | |
| Cellulose (microcrystalline), NF § | TBD | | | | |
| Sodium Chloride, USP | As required | | | | |

- * Takes into account increased batch size conversions and density conversions, if required.
- § Weigh / measure just prior to use.

Preparatory Instruction

| | |
|----|---|
| 1. | <p><u>Excipient requirements for 100 x size #0 capsules</u></p> <p>A. Calculate the amount of Cellulose (microcrystalline) and Hypromellose (4000 CPS) Methocel E4M required for the batch. Refer to attached appendix for details.</p> |
| 2. | <p><u>Powder preparation:</u></p> <p>A. Triturate the Diltiazem Hydrochloride to form a fine, homogeneous powder.</p> <p>B. <u>By geometric addition</u>, combine and mix the following ingredients together to form a homogeneous powder blend:</p> <ul style="list-style-type: none"> -Fine, homogeneous powder (Step 2A) -Cellulose (microcrystalline) (Quantity determined in appendix (J)) -Hypromellose (4000 CPS) Methocel E4M (Quantity determined in appendix (L)) <p><u>End result:</u> Homogeneous powder blend.</p> |
| 3. | <p><u>Product transfer:</u></p> <p>Fill each of 100 Size #0 capsules with the mixture (Step 2B). Close each capsule tightly.</p> <p>Clean each capsule by placing the capsules in a container filled with Sodium chloride, and then gently rolling the container. Pour the container contents into a 10-mesh sieve, and allow the Sodium chloride to pass through. Finally, roll the capsules on a cloth-covered surface.</p> |
| 4. | <p><u>Validation technique (average capsule weight):</u></p> <p>The final weight of each capsule (not including capsule shell) should fall between 90 and 110% of the theoretically calculated weight, in accordance to USP 795 guidelines. The theoretically calculated weight can be determined by adding the amount in appendix (D) + (H) + 0.240 g together.</p> |



| | | | |
|-------------------|---|-----|-----------|
| Suggested Formula | Diltiazem Hydrochloride 240 mg Slow Release Oral Capsules (Powder Blend, 100 x Size #0 Capsules) | FIN | F 008 143 |
|-------------------|---|-----|-----------|

| | |
|----|---|
| 5. | <u>Product transfer:</u> Transfer the final product into the specified dispensing container (see “Packaging Requirements”). |
|----|---|

SUGGESTED PRESENTATION

| Estimated Beyond-Use Date | | Packaging Requirements | |
|---------------------------|--|--|---|
| | 6 months, as per USP*. | | Tightly closed, light-resistant capsule shells and vials. |
| Auxiliary Labels | 1 | Use as directed. Do not exceed prescribed dose. | 6 |
| | 2 | Keep out of reach of children. | 7 |
| | 3 | Protect from light. | 8 |
| | 4 | May impair mental and/or physical ability. Use care when operating a car or machinery. | 9 |
| | 5 | Keep in a dry place. | 10 |
| Pharmacist Instructions | Add any auxiliary labels specific to the API to the dispensing container as deemed necessary. | | |
| Patient Instructions | Contact your pharmacist in the event of adverse reactions. IMPORTANT: The quantity of API administered is directly dependent on the quantity of product applied. | | |

* **The BUD is not later than the time remaining until the earliest expiration date of any API or 6 months, whichever is earlier.**



| | | | |
|-------------------|---|-----|-----------|
| Suggested Formula | Diltiazem Hydrochloride 240 mg Slow Release Oral Capsules (Powder Blend, 100 x Size #0 Capsules) | FIN | F 008 143 |
|-------------------|---|-----|-----------|

REFERENCES

| | |
|----|--|
| 1. | Capsules. In: Allen, LV, Jr. <i>The Art, Science, and Technology of Pharmaceutical Compounding Fifth Edition</i> . American Pharmacists Association; 2016: 189. |
| 2. | Cellulose (microcrystalline). In: Rowe RC. <i>Handbook of Pharmaceutical Excipients, 7th Edition</i> . American Pharmaceutical Association; 2012: 140. |
| 3. | Hypromellose. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients, 7th Edition</i> . American Pharmaceutical Association; 2012: 373. |
| 4. | Sodium Chloride. In: Rowe RC. <i>Handbook of Pharmaceutical Excipients, 7th Edition</i> . American Pharmaceutical Association; 2012: 729. |
| 5. | Diltiazem Hydrochloride. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference, 36th Edition</i> . London, England: The Pharmaceutical Press; 2009: 1265. |
| 6. | Diltiazem Hydrochloride (Monograph). In: O'Neil MJ. <i>The Merck Index 15th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2013: Monograph #3224. |
| 7. | Diltiazem Hydrochloride. In: Trissel LA. <i>Trissel's Stability of Compounded Formulations, 5th Edition</i> . American Pharmaceutical Association; 2012: 168. |
| 8. | Diltiazem Hydrochloride (Monograph). <i>United States Pharmacopeia XLI / National Formulary 36</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2018: 1040. |
| 9. | USP <795>. <i>United States Pharmacopeia XLI / National Formulary 36</i> . Rockville, MD. US Pharmacopeial Convention, Inc. 2018: 6546. |

DISCLAIMER: MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY, SCHEDULING OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW. MEDISCA NETWORK INC. MAKES NO WARRANTIES WITH RESPECT TO INFRINGEMENT OR NON-INFRINGEMENT BY THE FORMULA OF ANY PATENT OR OTHER INTELLECTUAL PROPERTY OF ANY OTHER PARTY, AND IT IS THE RESPONSIBILITY OF THE PHARMACIST TO INVESTIGATE AND DETERMINE ANY SUCH ISSUE.



| | | | |
|----------|--|--|--|
| Appendix | Calculating the quantity of excipient required for the batch | | |
|----------|--|--|--|

| Procedure | | | | | | | | | | | | | | | | | | | | | | | |
|-------------------------------------|---|--|--|--------------------|--|--|--|----------------------------|---------|---------|---------|-------------------------------------|----------------------------------|---------|-----|---------------------------------|--|---------|--|----------------------------------|--|--|-------------|
| 1. | <p><u>Capsule filling:</u></p> <p>a. For <u>each</u> ingredient powder below, determine the average capsule fill weight by filling and weighing five TARED CAPSULES. Do not forget to divide the total weight by 5 to obtain an <u>average</u> capsule fill weight. Also, crush and triturate the ingredient first if required in formulation.</p> <p>Plug each amount into Step 2, column B.</p> | | | | | | | | | | | | | | | | | | | | | | |
| 2. | <p><u>Volume Percent Occupied:</u></p> <table style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th style="text-align: left; width: 35%;"><u>Ingredients</u></th> <th style="text-align: center; width: 20%;">Column A Quantity Required per capsule</th> <th style="text-align: center; width: 20%;">Column B Average capsule fill weight</th> <th style="text-align: center; width: 25%;">Column C A/B x 100 equals percent filled</th> </tr> </thead> <tbody> <tr> <td>a. Diltiazem Hydrochloride</td> <td style="text-align: center;">0.240 g</td> <td style="text-align: center;">_____ g</td> <td style="text-align: center;">_____ %</td> </tr> <tr> <td>b. Hypromellose (4000 CPS) Methocel</td> <td style="text-align: center;">_____ g (D) (0.40 x column B)</td> <td style="text-align: center;">_____ g</td> <td style="text-align: center;">40%</td> </tr> <tr> <td>c. Cellulose (microcrystalline)</td> <td></td> <td style="text-align: center;">_____ g</td> <td></td> </tr> <tr> <td>d. Total (add column C together)</td> <td></td> <td></td> <td style="text-align: center;">_____ % (E)</td> </tr> </tbody> </table> | | | <u>Ingredients</u> | Column A Quantity Required per capsule | Column B Average capsule fill weight | Column C A/B x 100 equals percent filled | a. Diltiazem Hydrochloride | 0.240 g | _____ g | _____ % | b. Hypromellose (4000 CPS) Methocel | _____ g (D) (0.40 x column B) | _____ g | 40% | c. Cellulose (microcrystalline) | | _____ g | | d. Total (add column C together) | | | _____ % (E) |
| <u>Ingredients</u> | Column A Quantity Required per capsule | Column B Average capsule fill weight | Column C A/B x 100 equals percent filled | | | | | | | | | | | | | | | | | | | | |
| a. Diltiazem Hydrochloride | 0.240 g | _____ g | _____ % | | | | | | | | | | | | | | | | | | | | |
| b. Hypromellose (4000 CPS) Methocel | _____ g (D) (0.40 x column B) | _____ g | 40% | | | | | | | | | | | | | | | | | | | | |
| c. Cellulose (microcrystalline) | | _____ g | | | | | | | | | | | | | | | | | | | | | |
| d. Total (add column C together) | | | _____ % (E) | | | | | | | | | | | | | | | | | | | | |
| 3. | <p><u>Calculate the quantity of Cellulose and Hypromellose required for the batch:</u></p> <p>a. Percent of Cellulose (microcrystalline) required = 100% – E _____ % (F)</p> <p>b. Average capsule fill weight of Cellulose (microcrystalline) (from column B, Step 2c): _____ g (G)</p> <p>c. Quantity of Cellulose (microcrystalline) required per capsule = [(F) ÷ 100 × (G)] _____ g (H)</p> <p>d. Total Quantity of Cellulose (microcrystalline) required for the batch = 100 capsules × (H) _____ g (I)</p> <p>e. Total quantity of Cellulose (microcrystalline) <i>plus</i> processing error = (I) × 1.03-1.05 _____ g (J)</p> <p>f. Total quantity of Hypromellose (4000 CPS) Methocel required for the batch = 100 capsules × (D) _____ g (K)</p> <p>g. Total quantity of Hypromellose (4000 CPS) Methocel <i>plus</i> processing error = (K) × 1.03-1.05 _____ g (L)</p> | | | | | | | | | | | | | | | | | | | | | | |

DISCLAIMER: MEDISCA NETWORK INC., HEREBY REFERRED TO AS 'THE NETWORK', HAS PROVIDED THE FORMULA AND INSTRUCTIONS ABOVE AS A MODEL FOR EDUCATIONAL PURPOSES ONLY ON THE BASIS OF THE RECOGNIZED COMPENDIA AND TEXTS REFERENCED AT THE END OF THIS DOCUMENT. THE NETWORK TAKES NO RESPONSIBILITY FOR THE VALIDITY, SCHEDULING OR ACCURACY OF THIS INFORMATION OR FOR ITS SAFETY OR EFFECTIVENESS, NOR FOR ANY USE THEREOF, WHICH IS AT THE SOLE RISK OF THE LICENSED PHARMACIST. ADJUSTMENTS MAY BE NEEDED TO MEET SPECIFIC PATIENT NEEDS AND IN ACCORDANCE WITH A LICENSED PRESCRIBER'S PRESCRIPTION. THE PHARMACIST MUST EMPLOY APPROPRIATE TESTS TO DETERMINE THE STABILITY OF THIS SUGGESTED FORMULA. THE NETWORK CANNOT BE HELD LIABLE TO ANY PERSON OR ENTITY CONCERNING CLAIMS, LOSS, OR DAMAGE CAUSED BY, OR ALLEGED TO BE CAUSED BY, DIRECTLY OR INDIRECTLY, THE USE OR MISUSE OF THE INFORMATION CONTAINED IN THIS SUGGESTED FORMULA. IN ALL CASES IT IS THE RESPONSIBILITY OF THE LICENSED PHARMACIST TO KNOW THE LAW, TO COMPOUND ANY FINISHED PRODUCT AND TO DISPENSE THESE PRODUCTS IN ACCORDANCE WITH FEDERAL AND STATE LAW. MEDISCA NETWORK INC. MAKES NO WARRANTIES WITH RESPECT TO INFRINGEMENT OR NON-INFRINGEMENT BY THE FORMULA OF ANY PATENT OR OTHER INTELLECTUAL PROPERTY OF ANY OTHER PARTY, AND IT IS THE RESPONSIBILITY OF THE PHARMACIST TO INVESTIGATE AND DETERMINE ANY SUCH ISSUE.